These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30128073)

  • 1. Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor.
    Stachel SJ; Berger R; Nomland AB; Ginnetti AT; Paone DV; Wang D; Puri V; Lange H; Drott J; Lu J; Marcus J; Dwyer MP; Suon S; Uslaner JM; Smith SM
    ACS Med Chem Lett; 2018 Aug; 9(8):815-820. PubMed ID: 30128073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.
    Stachel SJ; Egbertson MS; Wai J; Machacek M; Toolan DM; Swestock J; Eddins DM; Puri V; McGaughey G; Su HP; Perlow D; Wang D; Ma L; Parthasarathy G; Reid JC; Abeywickrema PD; Smith SM; Uslaner JM
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1122-1126. PubMed ID: 29534798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.
    Buijnsters P; De Angelis M; Langlois X; Rombouts FJ; Sanderson W; Tresadern G; Ritchie A; Trabanco AA; VanHoof G; Roosbroeck YV; Andrés JI
    ACS Med Chem Lett; 2014 Sep; 5(9):1049-53. PubMed ID: 25221665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
    Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
    Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
    Qiu X; Huang Y; Wu D; Mao F; Zhu J; Yan W; Luo HB; Li J
    Bioorg Med Chem; 2018 Jan; 26(1):119-133. PubMed ID: 29174506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
    Huang XF; Cao YJ; Zhen J; Zhang DW; Kong R; Jiang WT; Xu Y; Song GQ; Ke HM; Liu L
    Bioorg Med Chem Lett; 2019 Feb; 29(3):481-486. PubMed ID: 30554955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
    Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
    Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.
    Forster AB; Abeywickrema P; Bunda J; Cox CD; Cabalu TD; Egbertson M; Fay J; Getty K; Hall D; Kornienko M; Lu J; Parthasarathy G; Reid J; Sharma S; Shipe WD; Smith SM; Soisson S; Stachel SJ; Su HP; Wang D; Berger R
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5167-5171. PubMed ID: 29113762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.
    Rombouts FJ; Tresadern G; Buijnsters P; Langlois X; Tovar F; Steinbrecher TB; Vanhoof G; Somers M; Andrés JI; Trabanco AA
    ACS Med Chem Lett; 2015 Mar; 6(3):282-6. PubMed ID: 25815146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity.
    Zhu J; Yang Q; Dai D; Huang Q
    J Am Chem Soc; 2013 Aug; 135(32):11708-11. PubMed ID: 23899287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined 2D and 3D-QSAR, molecular modelling and docking studies of pyrazolodiazepinones as novel phosphodiesterase 2 inhibitors.
    Bhansali SG; Kulkarni VM
    SAR QSAR Environ Res; 2014; 25(11):905-37. PubMed ID: 25401514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
    Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
    Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
    Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
    Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.
    Abusnina A; Keravis T; Zhou Q; Justiniano H; Lobstein A; Lugnier C
    Thromb Haemost; 2015 Feb; 113(2):319-28. PubMed ID: 25230992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of phosphodiesterase 2 in the central nervous and peripheral systems.
    Zhang C; Yu Y; Ruan L; Wang C; Pan J; Klabnik J; Lueptow L; Zhang HT; O'Donnell JM; Xu Y
    Curr Pharm Des; 2015; 21(3):274-90. PubMed ID: 25159070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice.
    Lueptow LM; Zhan CG; O'Donnell JM
    Psychopharmacology (Berl); 2016 Feb; 233(3):447-56. PubMed ID: 26525565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
    Mikami S; Sasaki S; Asano Y; Ujikawa O; Fukumoto S; Nakashima K; Oki H; Kamiguchi N; Imada H; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7658-7676. PubMed ID: 28759228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pde2 gene of Saccharomyces cerevisiae is allelic to rca1 and encodes a phosphodiesterase which protects the cell from extracellular cAMP.
    Wilson RB; Renault G; Jacquet M; Tatchell K
    FEBS Lett; 1993 Jul; 325(3):191-5. PubMed ID: 8391474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.